Novo Nordisk A/S (NYSE:NVO) Receives $53.33 Consensus PT from Analysts

by · The Markets Daily

Novo Nordisk A/S (NYSE:NVO – Get Free Report) has been assigned an average rating of “Hold” from the twenty-two brokerages that are presently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $53.3333.

NVO has been the subject of several research reports. Rothschild & Co Redburn raised Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 16th. The Goldman Sachs Group cut their price target on Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating on the stock in a research report on Friday, November 28th. Berenberg Bank upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, September 17th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, September 9th. Finally, BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research note on Tuesday.

Get Our Latest Research Report on NVO

Novo Nordisk A/S Stock Down 0.5%

NVO stock opened at $52.29 on Wednesday. The company’s 50 day moving average is $49.35 and its two-hundred day moving average is $56.93. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $93.80. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. The stock has a market cap of $233.49 billion, a P/E ratio of 15.20 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The firm had revenue of $11.79 billion for the quarter, compared to the consensus estimate of $11.98 billion. Research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Novo Nordisk A/S

Hedge funds and other institutional investors have recently bought and sold shares of the company. Academy Capital Management raised its position in Novo Nordisk A/S by 0.3% during the 3rd quarter. Academy Capital Management now owns 367,419 shares of the company’s stock worth $20,388,000 after buying an additional 1,170 shares during the last quarter. IFP Advisors Inc raised its holdings in Novo Nordisk A/S by 21.1% during the third quarter. IFP Advisors Inc now owns 13,712 shares of the company’s stock worth $761,000 after purchasing an additional 2,391 shares in the last quarter. Innova Wealth Partners lifted its position in Novo Nordisk A/S by 35.6% in the third quarter. Innova Wealth Partners now owns 4,091 shares of the company’s stock valued at $227,000 after purchasing an additional 1,073 shares during the period. Tevis Investment Management boosted its holdings in Novo Nordisk A/S by 12.1% in the 3rd quarter. Tevis Investment Management now owns 44,700 shares of the company’s stock valued at $2,480,000 after purchasing an additional 4,838 shares in the last quarter. Finally, XXEC Inc. increased its position in Novo Nordisk A/S by 26.7% during the 3rd quarter. XXEC Inc. now owns 99,075 shares of the company’s stock worth $5,498,000 after purchasing an additional 20,890 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Company Profile

(Get Free Report)

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

Featured Stories